SCHEMBL3373386

SCHEMBL3373386

COCCOc1cc(O)c2cccc(Cl)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
NR4A2 P43354 4/20 0.38
MAPK14 Q16539 2/20 0.37
KCNJ5 P48544 2/20 0.35
KCNJ3 P48549 2/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
PARP1 P09874 2/20 0.35
KDM1A O60341 1/20 0.34
CRHR1 P34998 1/20 0.34
KDR P35968 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
FGFR1 P11362 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021189 0.85 NR4A2 (0.41) SMN1; SMN2ALDH1A1KDM4EHTTNR4A2
SCHEMBL13763686 0.84 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1KDM4EHTTHSD17B10
SCHEMBL3375748 0.83 NR4A2 (0.44) SMN1; SMN2KDM4ENR4A2HSP90AA1PARP1
SCHEMBL13763607 0.82 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1KDM4EHTTHSD17B10
SCHEMBL8145393 0.82 NR4A2 (0.37) SMN1; SMN2ALDH1A1KDM4EHTTHSD17B10
SCHEMBL15483739 0.82 NR4A2 (0.37) SMN1; SMN2ALDH1A1KDM4EHTTHSD17B10
SCHEMBL13248807 0.81 NR4A2 (0.40) KDM4EHTTNR4A2PARP1BTK
SCHEMBL13757467 0.81 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1KDM4EHTTHSD17B10
SCHEMBL8136117 0.80 S1PR4 (0.35) KDRPOLBFGFR1FLT1
SCHEMBL13757511 0.80 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KDM4EHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809267-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-08-19 US disclosed
US-20140051626-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 US disclosed
US-20140051626-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 US disclosed
US-20140051626-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 US disclosed
US-8513186-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-08-20 US disclosed
US-8513186-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-08-20 US disclosed
US-8513186-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-08-20 US disclosed
EP-2162432-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2010-03-17 EP disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 SMN1; SMN2 1564/4885ALDH1A1 3957/4885KDM4E 2496/4885
US-20140051626-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 SMN1; SMN2 1564/4885ALDH1A1 3957/4885KDM4E 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.